Skip to main content

Site notifications

Notice for Dexrazoxane (Reach Pharmaceuticals Pty Ltd)

Active ingredients
Dexrazoxane
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
powder for injection
Indication
For use in the prevention of cardiotoxicity caused by anthracycline use
Therapeutic area
Cardiovascular

Help us improve the Therapeutic Goods Administration site